{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:51:16Z","timestamp":1761519076116,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2002,5]]},"DOI":"10.4158\/ep.8.3.202","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T23:42:05Z","timestamp":1365205325000},"page":"202-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Response of Bone Mineral Density to Once-Weekly Administration of Risedronate"],"prefix":"10.1016","volume":"8","author":[{"given":"Michael S.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray B.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP.8.3.202_bb0005","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM199503233321202","article-title":"Risk factors for hip fracture in white women: study of Osteoporotic Fractures Research Group","volume":"332","author":"Cummings","year":"1995","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.8.3.202_bb0010","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1359\/jbmr.1999.14.5.821","article-title":"Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures: study of Osteoporotic Fractures Research Group","volume":"14","author":"Black","year":"1999","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.8.3.202_bb0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF01623273","article-title":"Changing incidence and residual lifetime risk of common osteoporosis-related fractures","volume":"3","author":"Lauritzen","year":"1993","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP.8.3.202_bb0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1620\/tjem.188.139","article-title":"Determining factors of mortality in the elderly with hip fractures","volume":"188","author":"Koike","year":"1999","journal-title":"Tohoku J Exp Med."},{"key":"10.4158\/EP.8.3.202_bb0025","first-page":"269","article-title":"Mortality after hip fracture: regional variations in New Zealand","volume":"112","author":"Walker","year":"1999","journal-title":"N Z Med J."},{"key":"10.4158\/EP.8.3.202_bb0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0149-2918(00)87974-6","article-title":"Weekly administration of alendronate: rationale and plan for clinical assessment","volume":"22","author":"Bone","year":"2000","journal-title":"Clin Ther."},{"key":"10.4158\/EP.8.3.202_bb0035","first-page":"1","article-title":"(Once-Weekly Study Group). Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging (Milano)."},{"key":"10.4158\/EP.8.3.202_bb0040","first-page":"1377","article-title":"Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis","volume":"4","author":"Ettinger","year":"1998","journal-title":"Am J Manag Care."},{"key":"10.4158\/EP.8.3.202_bb0045","doi-asserted-by":"crossref","first-page":"488","DOI":"10.18553\/jmcp.1998.4.5.488","article-title":"Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation","volume":"4","author":"Ettinger","year":"1998","journal-title":"J Managed Care Pharm."},{"key":"10.4158\/EP.8.3.202_bb0050","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"de Groen","year":"1996","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.8.3.202_bb0055","first-page":"704","article-title":"A new probable increasing cause of esophageal ulceration: alendronate","volume":"92","author":"Colina","year":"1997","journal-title":"Am J Gastroenterol."},{"key":"10.4158\/EP.8.3.202_bb0060","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0002-9343(97)89446-6","article-title":"Esophageal stricture associated with alendronate therapy","volume":"102","author":"Levine","year":"1997","journal-title":"Am J Med."},{"key":"10.4158\/EP.8.3.202_bb0065","first-page":"S469","article-title":"Side effect profile of alendronate in clinical practice [abstract]","volume":"12","author":"Daoud","year":"1997","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP.8.3.202_bb0070","unstructured":"Adachi JD, Adami S, Miller PD, et al. Tolerability of risedronate in alendronate-intolerant women [abstract #822]. Presented at: 64th Annual Scientific Meeting of the American College of Rheumatology; Oct 29-Nov 1, 2000; Philadelphia, PA."},{"key":"10.4158\/EP.8.3.202_bb0075","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1053\/gast.2000.16517","article-title":"Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women","volume":"119","author":"Lanza","year":"2000","journal-title":"Gastroenterology."},{"key":"10.4158\/EP.8.3.202_bb0080","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1023\/A:1005574009856","article-title":"Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa","volume":"45","author":"Lichtenberger","year":"2000","journal-title":"Dig Dis Sci."},{"key":"10.4158\/EP.8.3.202_bb0085","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00002512-199813010-00008","article-title":"Risedronate","volume":"13","author":"Goa","year":"1998","journal-title":"Drugs Aging."},{"key":"10.4158\/EP.8.3.202_bb0090","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00003088-199936050-00002","article-title":"Pharmacokinetics of alendronate","volume":"36","author":"Porras","year":"1999","journal-title":"Clin Pharmacokinet."},{"key":"10.4158\/EP.8.3.202_bb0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S8756-3282(97)00222-6","article-title":"Paget\u2019s disease of bone: reduction of disease activity with oral risedronate","volume":"22","author":"Hosking","year":"1998","journal-title":"Bone."},{"key":"10.4158\/EP.8.3.202_bb0100","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.4158\/EP.8.3.202_bb0105","first-page":"1890","article-title":"Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women","volume":"86","author":"Harris","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.8.3.202_bb0110","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"(Hip Intervention Program Study Group). Effect of rised-ronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20400758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20400758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/K6ECQTLN1TG3PHG9.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:41:28Z","timestamp":1761514888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20400758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["S1530891X20400758"],"URL":"https:\/\/doi.org\/10.4158\/ep.8.3.202","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2002,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response of Bone Mineral Density to Once-Weekly Administration of Risedronate","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP.8.3.202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}